Nature: Discover the most effective SARS-CoV-2 virus neutralizing antibodies!

27, 2020 /PRNewswire/ -- Researchers at Columbia University's Irvine Medical Center isolated the most effective SARS-CoV-2 virus neutral antibodies to date from several PATIENTs with COVID-19.these antibodies can be produced in large quantities by pharmaceutical companies to treat patients, especially in the early stages of infection, and to prevent infection -- especially in the elderly. "We now have a range of more effective and diverse neutral antibodies than other previously discovered antibodies, and we are ready to develop these antibodies for treatment,".," said Dr. David Ho, a professor of medicine at Columbia University's Waglos School of Medicine and Surgery and scientific director of the Allen Diamond AIDS Research Center.researchers have confirmed that their purified strong neutralizing antibodies provide significant protection against the HAMster's SARS-CoV-2 infection, and they plan to conduct further studies in other animals and humans.study was published recently in the journal Nature.Picture Source: David. One of the main responses to infection in the search for neutralizing antibodies in the Columbia University Irving Medical Center is to produce antibodies -- a protein that binds to an invading pathogen to neutralise it and marks it destroyed by immune system cells.Although clinical trials are under way on some of the drugs and vaccines being developed for COVID-19, they may have to wait months to be ready.during this period, PATIENTS WITH COVID-19 PRODUCED SARS-CoV-2 neutralizing antibodies can be used to treat other patients and even prevent infection in people exposed to the virus. the development and approval of antibodiesis usually shorter than conventional drugs.this method is similar to the recovery period serum used in patients with COVID-19, but may be more effective.recovery serum contains a variety of antibodies, but because each patient's immune response is different, the antibody-rich plasma used to treat one patient may be very different from the plasma used to treat another patient, with different concentrations and strengths of neutralizing antibodies.develop stronger antibodies in patients with worsening conditions When SARS-CoV-2 appeared early in the year and led to a pandemic, Ho quickly shifted the focus of his HIV/AIDS lab to studying the new virus. "Most of my team members have been working 24 hours a day, 7 days, from the beginning of March," saysHo." researchers could easily obtain blood samples from patients with moderate and severe illnesses treated at Columbia University Irving Medical Center in New York City.New York City was at the center of an outbreak earlier this year. "We have a large number of clinical materials that allow us to choose the best cases to isolate these antibodies,"." Ho's team found that although many patients infected with SARS-CoV-2 produce large amounts of antibodies, the mass of these antibodies varies.of the patients they studied, those with serious illnesses that required mechanical ventilation produced the most neutralized antibodies. "We think that more serious patients contract the virus longer, causing their immune systems to respond more aggressively," Ho said." is similar to what we have learned from the experience of AIDS." antibody cocktailmost most anti-SARS-CoV-2 antibodies bind to the stingy glycoprotein on the surface of the virus, which is a characteristic of the coronal structure that gives the virus.some of the most effective antibodies are directed to the receptor binding region (the region where the virus binds to human cells), but other antibodies are directed to the N-side region of the stingprotein.the team found more diverse antibodies than before, including new, unique antibodies that had not been previously reported.these findings show which sites are most vulnerable on the viral protrusion protein, and the use of different antibody mixtures for different sites of the sting protein will help prevent the virus from developing resistance to treatment.effects on vaccines" we found that it is not difficult for the immune system to produce these powerful antibodies.this bodes well for vaccine development.vaccines that produce strong neutral antibodies should provide strong protection against the virus." Antibodies may be useful even after the vaccine is available.", for example, that vaccines may not work in older people, in which case antibodies may play a key role in protecting older people.Picture Source: David. The impact of immunization at Columbia University Irving Medical Center shows that patients with severe diseases are more likely to produce a lasting antibody response, but more research is needed to answer the key question of how long COVID-19 immunity will last.what next researchers are currently designing experiments to test the strategy in other animals and eventually in humans. if the results of animal experiments are also applicable to humans, then this pure, highly neutral antibody can be used in patients with COVID-19 to help them remove the virus. warn that while the findings provide huge information for researchers developing vaccines and antiviral therapies, they are early preclinical results and are not ready for use in humans. () References: Neutralantibodies isolated with from COVID-19 Patients May Sei-Bres si-Virus Liu, L., Wang, P., Nair, M.S. et al. Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike. Nature (2020). DOI: 10.1038/s41586-020-2571-7.